Brain natriuretic peptide and N-terminal pro-B-type natriuretic peptide show a different profile in response to acute decompensated heart failure treatment.
Brain natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are currently used for the diagnosis, prognosis, and therapeutic decision making in heart failure patients. The aim of the study was to compare BNP and NT-proBNP plasma concentration profiles in 42 patients with decompensated heart failure who underwent treatment in the emergency department. A significant decrease in both peptide concentrations fell beyond 24 hours of therapy. BNP concentration underwent a more responsive change from admission (-54.1%+/-8.6% at 72 hours and -57.4%+/-7.6% at discharge) than NT-proBNP concentration (-17.6%+/-5.4% at 72 hours and -18.6%+/-5.6% at discharge). Although BNP and NT-proBNP concentrations were highly correlated, no correlation in their variations was found, a finding that suggests a different kinetic behavior in response to treatment. Sequential measurements of BNP and NT-proBNP provide a reliable marker to confirm clinical improvement after 24 hours of treatment. BNP may show some advantages over NT-proBNP as a more sensitive marker of early stabilization in response to therapy.
Di Somma
Salvatore
S
Emergency Medicine Department, II Medical School University La Sapienza, Sant'Andrea Hospital, Rome, Italy. salvatore.disomma@uniroma1.it
Magrini
Laura
L
Tabacco
Fabio
F
Marino
Rossella
R
Talucci
Veronica
V
Marrocco
Francesca
F
Cardelli
Patrizia
P
Ferri
Enrico
E
Pittoni
Valerio
V
D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers; D005260:Female; D006305:Health Status Indicators; D006333:Heart Failure / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D011379:Prognosis; D018570:Risk Assessment; D016896:Treatment Outcome
D015415:Biomarkers; D020097:Natriuretic Peptide, Brain